These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10464658)

  • 21. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age.
    Nakata N; Wang Y; Bhatt S
    Prenat Diagn; 2010 Mar; 30(3):198-206. PubMed ID: 20063323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antenatal screening for Down syndrome.
    Wald NJ
    Prog Clin Biol Res; 1995; 393():27-42. PubMed ID: 8545455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective analysis of amniocenteses performed for advanced maternal age and various other indications in Turkish women.
    Danisman N; Kahyaoglu S; Celen S; Kahyaoglu I; Candemir Z; Yesilyurt A; Cakar ES
    J Matern Fetal Neonatal Med; 2013 Feb; 26(3):242-5. PubMed ID: 23025698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The prenatal diagnosis of Down's syndrome based on the biochemical screening of maternal serum markers].
    Arbuzova SB; Nikolenko MI; Khlevnaia LA; Fedotova OO; Solov'eva VD; Malova SA
    Tsitol Genet; 1998; 32(1):66-71. PubMed ID: 9695254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of first-trimester screening on AMA patients' uptake of invasive testing.
    Wray AM; Ghidini A; Alvis C; Hodor J; Landy HJ; Poggi SH
    Prenat Diagn; 2005 May; 25(5):350-3. PubMed ID: 15906421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 46,XY,i(21q) identified by maternal serum screening.
    Meyers CM; Ghori S; Roberson AE; Blitzer MG; Cohen MM
    Md Med J; 1997 Feb; 46(2):88-9. PubMed ID: 9029908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Maternal age in pregnancy--genetic counseling and prenatal diagnosis in the light of known facts and personal observations].
    Chrzanowska K; Krajewska-Walasek M; Wiśniewski L
    Ginekol Pol; 1987 Oct; 58(10):656-61. PubMed ID: 2965077
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prenatal testing for Down syndrome in the Jewish and non-Jewish populations in Israel.
    Davidov B; Goldman B; Akstein E; Barkai G; Legum C; Dar H; Romem Y; Amiel A; Cohen H; Bach G
    Isr J Med Sci; 1994 Aug; 30(8):629-33. PubMed ID: 8045747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists.
    Egan JF; Kaminsky LM; DeRoche ME; Barsoom MJ; Borgida AF; Benn PA
    Am J Obstet Gynecol; 2002 Nov; 187(5):1230-4. PubMed ID: 12439510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-trimester combined screening for Down syndrome and other fetal anomalies.
    O'Leary P; Breheny N; Dickinson JE; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Obstet Gynecol; 2006 Apr; 107(4):869-76. PubMed ID: 16582125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling.
    Resta RG
    Am J Med Genet A; 2005 Feb; 133A(1):31-6. PubMed ID: 15637725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
    Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W; Vintzileos AM
    J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Counseling for low maternal serum alpha-fetoprotein should emphasize all chromosome anomalies, not just Down syndrome.
    Drugan A; Dvorin E; Koppitch FC; Greb A; Krivchenia EL; Evans MI
    Obstet Gynecol; 1989 Feb; 73(2):271-4. PubMed ID: 2463504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
    DiMaio MS; Baumgarten A; Greenstein RM; Saal HM; Mahoney MJ
    N Engl J Med; 1987 Aug; 317(6):342-6. PubMed ID: 2439909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of MSAFP screening on genetic services, 1984-1986.
    Greenberg F
    Am J Med Genet; 1988 Sep; 31(1):223-30. PubMed ID: 2464932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prenatal cytogenetic screening.
    Simpson JL
    Ultrasound Obstet Gynecol; 1995 Jan; 5(1):3-5. PubMed ID: 7531607
    [No Abstract]   [Full Text] [Related]  

  • 40. Congenital deficiency of AFP and Down syndrome screening.
    Sher C; Shohat M
    Prenat Diagn; 1997 Sep; 17(9):884-5. PubMed ID: 9316138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.